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neoadjuvant chemotherapy for node-negative
localized muscle-invasive urinary bladder cancer
resulted in comparable cystectomy-free survival
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Background: To retrospectively review the efficacy and organ preservation experience for muscle-invasive bladder
cancer by trimodality therapy at our institution.
Methods: Between July 2004 and February 2012, seventy patients (M/F = 55/15; median age = 69 years) of lymph
node negative localized muscle-invasive bladder cancer were treated primarily with trimodality approach including
transurethral resection of bladder tumor (TURBT) prior to combined chemotherapy and radiotherapy (CCRT).
Radiotherapy consisted of initial large field size irradiation with 3D conformal technique (3D-CRT), followed by
cone-down tumor bed boost with intensity modulated radiotherapy (IMRT) technique. The median total doses
delivered to bladder tumor bed and whole bladder were 59.4Gy and 40.0Gy, respectively. No patient received
neoadjuvant chemotherapy (NAC). Weekly cisplatin was administered during radiotherapy. Toxicity was scored
according to the RTOG criteria. Tumor response was evaluated both cystoscopically and radiographically 3
months after treatment.
Results: The numbers of patients with T2, T3 and T4 lesions were 41, 16 and 13, respectively. Overall survival
(OS) and progression-free survival (PFS) at 2 and 5 year were 65.7%, 51.9% and 50.8%, 39.9%, respectively, after a
median follow-up time of 24 months. Local-regional control and distant metastasis free survival at 2 year were
69.8% and 73.5%, respectively. Complete response (CR) rate assessed three month after CCRT was 78.1%. Ten
patients (20%) had local recurrence after initial CR (n = 50), 3 of them were superficial recurrence. One patient
underwent radical cystectomy after recurrence. The overall 5-year bladder intact survival was 49.0% (95% CI,
35.5% to 62.5%). Acute toxicities were limited to grade 1-2. One patient developed late grade 3 GU toxicity.
Conclusions: Our result suggested that trimodality bladder-sparing approach without NAC or dose-intensification
could be well-tolerated with a high CR rate and bladder preserving rate for muscle-invasive bladder cancer.
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Historically, surgery was the main treatment of muscle-
invasive bladder cancer. Radical cystectomy with urinary
diversion and pelvic lymph node dissection resulted in
5-year pelvic control rate of 80–90% and 5-year OS of
40–60% [1]. Radical cystectomy and partial cystectomy
(in selected cases) are frequently regarded as standard of
care in contemporary management of muscle-invasive
bladder cancer, where bladder-sparing radiotherapy was
used as an alternative. Compared with radiotherapy alone,
an OS benefit was observed with radical surgery in
patients with muscle-invasive bladder cancer [2]. The
introduction of bladder sparing therapy with or without
NAC besides CCRT had been pioneered by Tester et al
[3], Shipley et al [4] and Rodel et al [5]. CCRT has soon be
regarded as the mainstream of organ preservation therapy
instead of RT alone [6]. Although intriguing, the superior-
ity of NAC has not been proven in randomized trial [4].
However, most trimodality treatment consisted of NAC
followed by CCRT, with radical cystectomy reserved for
incomplete responders in these reports [7]. Overall, the
5-year OS was approximately 50% with three-quarters
of them maintaining functional bladders [7]. A trend to-
ward increasing the intensity of chemotherapy during
CCRT, such as the addition of vinblastine, paclitaxel
and gemcitabine to cisplatin [8-11], and escalation of
biological radiation dosage via hyperfractionation and
hypofractionation was noted [9,12]. However, late pelvic
toxicity are concerning. In spite of these encouraging
results and possible positive impact on quality of life
[13], widespread use of this technique was still limited.
In a report by Fedeli et al, the majority of muscle invasive
bladder cancer in the United States were still treated with
cystectomy (42.9%), while the minority were treated radi-
ation therapy (16.6%) [14].
We hereby report our institutional experience on blad-
der preservation using upfront CCRT without NAC or
adjuvant chemotherapy, with IMRT boost after whole
bladder irradiation by 3D-CRT.
Methods
Patient characteristics
Between July 2004 and February 2012, 91 patients diag-
nosed with muscle-invasive (T2 to T4) bladder cancer
who were treated with curative intent in our institution
were retrospectively reviewed. Patients with pelvic lymph
node metastases and distant metastases, as detected by
computed tomography (CT), magnetic resonance imaging
(MRI) or other modalities before RT were excluded in
this review. Seventy patients with newly diagnosed or
recurrent disease after initial TURBT treated with CCRT
after TURBT or partial cystectomy were included in this
analysis. This review was approved by the institutional
review board of our hospital (No.20130506R). T-categorywas re-assigned according to the American Joint Commit-
tee on Cancer (AJCC) tumor-node-metastasis classification
of 2010. The majority of patients included in the study had
pathological evidence of tumoral invasion of the muscular
layer, either after a TURBT (n = 64; 91.4%) or partial cystec-
tomy (n = 4, 5.7%). The remaining patients (n = 2; 2.9%)
received only biopsy, but had radiographical evidence of
T4 disease. The majority of the population had urothelial
cell carcinoma (n = 65, 92.9%). 55 of the patients (78.6%)
had high grade disease on pathology.
Treatment
Patients were referred from urologist. Those patients
were not candidates for radical cystectomy because of
comorbidities or personal preference. Radiotherapy was
performed 4 to 8 weeks after TURBT or partial cystec-
tomy. Planning CT scan with 3-mm slices was acquired
for all patients undergoing RT. The patients were simu-
lated in supine position with distended bladder. They
were instructed to void and take a fixed amount of fluid
(350-500 mL) thirty minutes prior to both simulation
and treatment. Large field irradiation to subclinical disease
by 3D-CRT followed by tumor-directed boost by IMRT
was our treatment guideline. High risk clinical target
volumes (CTV-H) were defined as preoperative tumor
bed, which were delineated on the planning CT with
respect to preoperative MRI or CT images registered by
image fusion. In those who underwent partial cystectomy,
the positions of surgical clips needed to be taken into con-
sideration for delineating CTV-H. In the presence of gross
residual tumor, the gross tumor volume (GTV) was delin-
eated on planning CT. The whole bladder was treated as
CTV-H in the presence of multifocal disease. A 1-2 cm
margin was added to CTV-H and GTV in all directions
to account for organ motion and formed the planning
target volume (PTV-H). IMRT was delivered via 4-10
MV photons using 5 to 7 static IMRT fields to PTV-H
volume. The clinical target volume at intermediate risk
(CTV-M) encompassed whole bladder in T2 disease
and included pelvic nodal regions (including hypogas-
tric, obturator, external iliac and perivesical nodes) in
T3 and T4 disease. A 2-cm margin was given to CTV-M
in the cranial and anterior directions and 1-cm in pos-
terior, lateral and caudal directions, forming PTV-M.
PTV-M was treated with 10 MV photons by 4-field 3D-
CRT technique. All treatment planning was performed
by Pinnacle version 9.0 (Philips Healthcare, Bothell,
WA).
RT was initiated 4 to 8 weeks after urological procedure.
Patients were treated with the same requirements as in
the planning phase. A median total dose of 59.4Gy (range,
44.5 to 66.6Gy) was delivered to the PTV-H, and the
PTV-M was irradiated with a median total dose of 40.0Gy
(range, 36.0 to 54.0Gy) at 1.8-2.0 Gy per daily fraction.
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volumes. The dose constraints were V55 < 50% for rectum,
and Dmax <45Gy to both bowels and femoral heads.
Concurrent platinum-based chemotherapy was offered
and consisted of cisplatin (30 mg/m2/week) for pa-
tients without impaired renal function defined as glom-
erular filtration rate (GFR) >50mL/min, or carboplatinTable 1 Patient, tumor and treatment-related
characteristics
Characteristics Value




History of prior TUR-BT
Initial treatment 50 (71.4%)









Transitional cell carcinoma 65 (92.9%)
Adenocarcinoma 1 (1.4%)















Procedure before radiotherapy (RT)
Transurethral resection (TUR) 64 (91.4%)
Partial cystectomy 4 (5.7%)
Cystoscopic biopsy only 2 (2.9%)(100 mg/m2 on days 1, 15, 31) for patients with renal
function impairment. The treatment-related characteris-
tics were summarized in Table 1.Follow-up and evaluation
Patients were observed at 3-month intervals for the first
3 years and every 6 months thereafter. Post-treatment
follow-up consisted of pertinent medical history, physical
examination, urine cytology, cystoscopy, and radiological
evaluation as clinically indicated. Tumor response was
evaluated using the Response Evaluation Criteria in
Solid Tumors (RECIST) [15] both cystoscopically and
radiographically (either CT or MRI) three months after
treatment. Complete response (CR) was defined as the
absence of detectable tumor as well as negative urine
cytology. Among patients with less than CR, cystec-
tomy was offered by the treating physicians. Salvage
therapy for non-muscle invasive recurrences consisted
of TUR-BT followed by intravesical therapy for non-
muscle invasive recurrence and radical cystectomy for
muscle-invasive recurrences. However, the final deci-
sion was determined at the discretion of urologist and
patient’s own will. In case of distant failure, combin-
ation cisplatin and gemcitabine was offered as first line
chemotherapy. Evaluation of late treatment-related tox-
icity was performed according to the toxicity criteria of
the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of
Cancer (EORTC) [16,17].Statistics
At the time of analysis, the median follow-up for the
entire group was 24months. Survival was measured
from the day of start of RT to the date of death or the
most recent follow-up visit. The OS and PFS was cal-
culated using the method of Kaplan-Meier and curve
comparison by log-rank test. Univariate and multivari-
ate analysis by Cox proportional hazards model were
performed to determine clinicopathological factors with
prognostic value for OS. A p-value <0.05 (two-sided) was
considered significant in all of the statistical testing. The
statistical analysis was performed using Statistical Package
for Social Sciences software for Windows version 13.0
(SPSS, Inc, Chicago, IL).Table 2 Tumor response after radiotherapy
Evaluable patients (n = 64)
Complete response (CR) 50 (78.1%)
Partial response (PR) 2 (3.1%)
Stable disease (SD) 3 (4.7%)
Progressive disease (PD) 9 (14.1%)
Table 3 Clinical outcomes
2-year rates 5-year rates
Overall survival 65.7% 50.8%
Bladder cancer specific survival 77.3% 67.3%
Survival with intact bladder* 64.2% 49.0%
Local-regional control 69.8% 61.7%
Distant-metastasis-free survival 73.5% 67.1%
Progression-free survival 51.9% 39.9%
*Only one patient with local failure received radical cystectomy as
salvage treatment.
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Tumor response after radiotherapy
Among the 70 patients, 64 patients were evaluable for
response (3 patients died of non-cancer comorbidities
shortly after treatment, and 3 patients refused cysto-
scopic evaluation). Of the evaluable 64 patients, 78.1%
(50 patients) achieved CR (Table 2). Of the remaining
patients with non-CR, two (3.1%) had partial response
(PR), three (4.7%) had stable disease, and nine (11.4%) had
progressive disease. Although radical cystectomy was
offered to all patients with less than CR, none of the
patients underwent this procedure due to patients'
refusal or medical inoperability.
Survival and bladder preservation
The median survival was 64.6 months after a median
follow-up of 24 months. OS and PFS at 2 year were





History of TURBT 0.986
ECOG performance status 3.182
Comorbidities 2.264
Clinical T stage 1.565
Hydronephrosis 1.825
RT duration, days 1.016
Concurrent chemotherapy 0.587
Prescribed doses to bladder tumor bed, Gy 0.914
Prescribed doses to whole bladder, Gy 1.001




Complete response (CR) 0.098metastasis free survival at 2 year were 69.8% and 73.5%,
respectively. Bladder cancer specific survival and survival
with intact bladder at 2 year were 77.3% and 64.2%
respectively. The clinical outcomes at 2 year and 5 year
were illustrated in Table 3.
Univariate analysis of 12 treatment-related factors
influencing OS was shown in Table 4. Age, performance
status, T stage, prescribed dose to primary site and CR
demonstrated significant hazard ratio on OS. Multivariate
analysis showed age, performance status and CR as inde-
pendent predictors on two-year overall survival (Table 4).
Two-year overall survival rate was statistically higher
among those with complete response than those without
(79.4% [95% CI, 67.2% to 91.6%] vs. 33.3% [95% CI, 7.6%
to 59.9%]; p < 0.001), while the median survival was 85.0
and 15.8 months (p < 0.001) (Figure 1).
Failure pattern
Of the 70 patients, isolated local-regional recurrence
was observed in 10 patients (15.6%); isolated distant me-
tastasis was observed in seven (9.4%); while both local-
regional and distant metastasis developed in 12 patients
(18.8%) (Figure 2). Of those 50 patients with CR, local
recurrence occurred in 10 patients during the course of
follow-up. Among whom six were muscle invasive, three
were superficial, and the remaining one had missing hist-
ology record (Table 5). Among patients who developed
muscle invasive recurrences, only one patient ultimately
underwent radical cystectomy as salvage treatment, while
the others refused salvage cystectomy or were medicallyctors on overall survival
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Figure 1 Overall survival of all patients and comparison between
CR and non-CR patients. (A) The median survival, 2-year and 5-year
OS rate of all patients were 64.6 months (95% CI, 32.3 to 97.0 months),
65.7% (95% CI, 52.6% to 76.0%), 50.8%. (95% CI, 36.7% to 63.2%). (B)
Two-year overall survival rate was statistically higher among those with
complete response than those without (79.4% [95% CI, 67.2% to 91.6%]












Figure 2 Failure pattern. The numbers in the circles were the
patient numbers of relevant failure patterns. The percentage of
relevant failure patterns were shown in the parentheses.






Papillary non-invasive carcinoma 1 (10%) Alive with NED: 1 patient
Flat carcinoma in situ 2 (20%) Alive with NED: 2 patients
Invasive urothelial carcinoma 6 (60%)
Alive with NED: 2 patients
Alive with distant mets:
1 patient
Expired: 3 patients
Missing record 1 (10%) Expired: 1 patient
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patients with superficial recurrences died, whereas three
of the invasive recurrences did. Distant metastasis devel-
oped in one of the surviving patients with muscle invasive
recurrences.
Acute toxicity and chronic sequelae
All of the radiation induced acute genitourinary (GU)
and gastrointestinal (GI) toxicities and were limited to
grade 2 (Table 6), and manageable. Acute grade 2 GUtoxicities accounted for 28.6% and grade 2 GI toxicities
in 11.4%. Chronic GU and GI toxicities of grade 2 or more
were encountered in 11 and 4 patients, respectively, while
no patient with ≧ grade 3 GI toxicity. Chronic grade 3 GU
toxicity developed in one patient and manifested as gross
hematuria and needed repeated blood transfusion. No
patient died from toxicities.
Discussion
A trimodality strategy for muscle-invasive bladder cancer
as the main treatment strategy for muscle-invasive bladder
cancer therapy has gained its popularity over time. How-
ever, an upfront CCRT approach without NAC is relatively
infrequent.
Despite the relatively low dose density of chemother-
apy in CCRT phase and a low radiation dose to the
whole bladder in this study, our result of a 5 year OS of
50.8% compared reasonably to most prospective trials
[7,9,18-20] and cystectomy series [21,22]. A clinical CR
rate of 78.1% and 5 year bladder intact survival of 49.0%
in this study also compared reasonably to most upfront
CCRT trials. Although NAC with platinum-based regi-
men before cystectomy compared to cystectomy was
associated with a 5% survival benefit, the possible benefit
of NAC before definitive CCRT has not been firmly estab-
lished. Most NAC trials were single-armed [8,10,23,24],
with one randomized trial demonstrating no statistically
significant benefit [4].
Table 6 Toxicities
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Acute GU toxicity 21 (30%) 20 (28. 6%) 0 (0%) 0 (0%) 0 (0%)
Acute GI toxicity 8 (11.4%) 8 (11.4%) 0 (0%) 0 (0%) 0 (0%)
Late GU toxicity 22 (31.4%) 10 (14.3%) 1 (1.43%) 0 (0%) 0 (0%)
Late GI toxicity 1 (1.43%) 4 (5.7%) 0 (0%) 0 (0%) 0 (0%)
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was not an exception in ours as most prospective
[4,19,25]and retrospective series [5,26,27]. In one retro-
spective series, CR in stage IV bladder cancer had
significantly better prognosis than those with stage II or
III disease but with no CR [26]. In this study, those who
failed to achieve CR fared poorly without radical cystec-
tomy. None of the non-CR patients was alive at 5 year.
The normogram developed at Massechuses General
Hospital (MGH) can be used to predict response to
CCRT, in which hydronephrosis was one of the poor
response indicators [28]. However, the presence of
hydronephrosis might not be a contraindication to blad-
der organ preservation treatment, because a significant
proportion of patients (43.3%) in our study presented
with hydronephrosis and the rate of CR was compatible
to most publications. Biomarkers might be useful to
better select patients for a trimodality approach and
should be evaluated in between prospective trials [29].
A total of 10 local recurrences (20%) developed among
50 CR patients. Thirty percent of them were superficial
recurrence whereas most of them were still muscle-
invasive. The proportion of muscle invasive recurrences
in our study seemed higher than other reports. In RTOG
95-06, the number of muscle invasive recurrence were
only half of superficial recurrences [19]. Our results of a
2-year bladder intact survival rate of 64.2% compared
favorably to the result of RTOG 8903 that had 99 patients
without hydronephrosis [4]. In our study, the overall 20%
recurrence rate in CR patients is close to that observed in
the Paris group, which reported a bladder recurrence rate
of 17% [30].
The optimal dose and fractionation of radiation may
be important in achieving a lasting response [31]. Hyper-
fractionation and hypofractionation were evaluated in
prospective trials [19,32]. Hypofractionated approach
had better gone through whole course IMRT in order to
spare normal organ at risk as much as possible. Current
radiation protocol for bladder preservation regarded whole
bladder dose of 54Gy and tumor bed 64-66Gy to be safe
[33]. As the results of BC2001 showed no statistically
increased toxicity with whole bladder irradiation to re-
duced high dose volume irradiation [34]. Organ motion
have attributed to the uncertainties in target delineation
and radiation delivery for bladder cancer treatment. Our
strictly enforced bladder filling policy protocol withoutimage-guided technique, although quite successful, should
be replaced by imaged guided technique, especially for the
part of tumor bed boost. The value of image guided radio-
therapy (IGRT) of bladder cancer should be the mainstay
of future work [35-37].
Unlike to the routine pelvic irradiation among RTOG
protocols [3,4,9,19], our bladder-only approach for T2
tumors and pelvic nodal coverage for T3, T4 lesions
seemed appropriate. In a large retrospective series by
Stein et al [38], incidence of lymph node involvement
was closely related to the T staging of the primary blad-
der tumor; the incidences of lymph node involvement
were 18% and 42% for T2 and T4 tumors, respectively.
Our radiation protocol resulted in low locoregional failure
rate (15.6%). In additional to the low incidence of regional
failure, our study also demonstrated very low incidence of
late grade toxicity (1.43% of late GU toxicity and 0% of
late GI toxicity). Acute grade 3 or more toxicity was not
seen. The bladder-only irradiation in combination with
3D-CRT and IMRT to T2 disease may be a sound alterna-
tive to pelvic irradiation.
The distant metastasis free survival rate in our study is
73.5% and 67.1% at 2- and 5-year, respectively. Extravesicle
diseases were consistently associated with high rates of
distant metastasis. The value of adjuvant chemotherapy in
bladder preservation was investigated in RTOG 97-06
[32]. Although the result was promising, less than half of
the enrolled patients completed the designated treatment.
Adjuvant chemotherapy was not part of our treatment
strategy in patients without pelvic node metastasis, even
though a substantial proportion of extravesicle tumors in
our study (T3 + T4 = 41.5%). Yet this did not jeopardize
our OS rate. Unless randomized trial has proven NAC
followed by CCRT and followed by chemotherapy is
better CCRT alone, our upfront CCRT strategy will be
continued.
Conclusions
Aim of bladder preservation therapy is to offer a quality
of life treatment and avoid potential morbidity from
chemotherapy or radiotherapy without compromising
bladder preservation rate. Upfront CCRT with mild
weekly cisplatin regimen without NAC or adjuvant
chemotherapy could provide reasonable CR rate, OS
and bladder preservation rate in T2-4N0 stage bladder
cancer patients.
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